HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer

MLA

Milana A. Bergamino, et al. “HER2-Enriched Subtype and Novel Molecular Subgroups Drive Aromatase Inhibitor Resistance and an Increased Risk of Relapse in Early ER+/HER2+ Breast Cancer.” EBioMedicine, vol. 83, Feb. 2022. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....0f2c36f0affe9cade26299ca49ee96f2&authtype=sso&custid=ns315887.

APA

Milana A. Bergamino, Elena López-Knowles, Gabriele Morani, Holly Tovey, Lucy Kilburn, Eugene F. Schuster, Anastasia Alataki, Margaret Hills, Hui Xiao, Chris Holcombe, Anthony Skene, John F. Robertson, Ian E. Smith, Judith M. Bliss, Mitch Dowsett, Maggie C.U. Cheang, Abigail Evans, Adrian Ball, Akhil Johri, … Zoe Winters. (2022). HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer. EBioMedicine, 83.

Chicago

Milana A. Bergamino, Elena López-Knowles, Gabriele Morani, Holly Tovey, Lucy Kilburn, Eugene F. Schuster, Anastasia Alataki, et al. 2022. “HER2-Enriched Subtype and Novel Molecular Subgroups Drive Aromatase Inhibitor Resistance and an Increased Risk of Relapse in Early ER+/HER2+ Breast Cancer.” EBioMedicine 83 (February). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....0f2c36f0affe9cade26299ca49ee96f2&authtype=sso&custid=ns315887.